Dr. Bass is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1314 E Sonterra Blvd
Suite 601
San Antonio, TX 78258Phone+1 210-490-0016Fax+1 210-490-3010
Summary
- I am a board-certified neurologist specializing in the diagnosis, treatment, and management of multiple sclerosis and other CNS demyelinating diseases. I am the Medical Director of the comprehensive MS clinic at the Neurology Center of San Antonio, which is affiliated and certified by the National Multiple Sclerosis Society.
Clinical Expertise
- Multiple sclerosis, Demyelinating diseases, Neuroimmunology (Multiple sclerosis)
Education & Training
- University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineResidency, Neurology, 1994 - 1997
- University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineInternship, Internal Medicine, 1993 - 1994
- The University of Texas Health Science Center at San AntonioClass of 1993
Certifications & Licensure
- TX State Medical License 1995 - 2026
- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Most Compassionate Doctor American Registry
- Super Doctor SuperDoctors.com
- Top MD Consumers Checkbook
Clinical Trials
- A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2) Start of enrollment: 2019 Jul 22
Roles: Principal Investigator
- Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls. Start of enrollment: 2022 Jan 25
- A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis Start of enrollment: 2022 May 03
- Join now to see all
Publications & Presentations
PubMed
- 13 citationsAutoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data.Alasdair J Coles, Joanne L Jones, Patrick Vermersch, Anthony Traboulsee, Ann D Bass
Multiple Sclerosis. 2022-04-01 - 20 citationsEffect of Multiple Sclerosis on Daily Activities, Emotional Well-being, and Relationships: The Global vsMS Survey.Ann D Bass, Bart Van Wijmeersch, Lori Mayer, Mathias Mäurer, Aaron Boster
International Journal of MS Care. 2020-07-01 - 35 citationsEfficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Ext...Tjalf Ziemssen, Ann D Bass, Regina Berkovich, Giancarlo Comi, Sara Eichau
CNS Drugs. 2020-09-01
Abstracts/Posters
- Efficacy of a fourth alemtuzumab course in RRMS patients from CARE-MS II who experienced disease activity after three prior coursesTraboulsee A, Alroughani R, Boster A, Bass A, Berkovich R, Fernandez O, Kim H-J, Limmroth V, Lycke J, Macdonell RAL, Singer BA, Vermersch P, Wiendl H, Ziemssen T, Mela..., 53rd CNSF Congress 2018, Halifax, Nova Scotia, Canada, 6/24/2018
- Efficacy of a Fourth Alemtuzumab Course in RRMS Patients With Disease Activity After Three Prior Courses: Analysis of CARE-MS IHeinz Wiendl1, Raed Alroughani2, Aaron Boster3, Anthony Traboulsee4, Ann D Bass5, Regina Berkovich6, Giancarlo Comi7, Óscar Fernández8, Ho Jin Kim9, Volker Limmroth10,..., EAN 2018, Lisbon, Portugal, 6/16/2018
- Efficacy of a Fourth Alemtuzumab Course in RRMS Patients With Disease Activity After Three Prior Courses: Analysis of CARE-MS IIBarry A Singer1, Raed Alroughani2, Aaron Boster3, Ann D Bass4, Regina Berkovich5, Giancarlo Comi6, Óscar Fernández7, Ho Jin Kim8, Volker Limmroth9, Jan Lycke10, Richar..., CMSC 2018, Nashville, TN, 5/30/2018
- Join now to see all
Press Mentions
- Merck Shares Advances in MS Portfolio with Key Efficacy and Safety Data at AAN 2022March 31st, 2022
- EMD Serono Shares Advances in MS Portfolio with Key Efficacy and Safety Data at AAN 2022March 31st, 2022
- Woman Learns to Embrace Life with Relapsing Multiple Sclerosis (MS)May 29th, 2019
- Join now to see all
Professional Memberships
- Member
- Texas Neurological SocietyMember
- National Multiple Sclerosis SocietyMember
- Member
- Consortium of Multiple Sclerosis CentersMember
Other Languages
- Vietnamese
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: